… TrkA inhibitory effects. This manuscript describes the development of an analgesic that
suppresses NGF/TrkA … describes the development of analgesics that target NGF/TrkA signaling. …

… of NGF-TrkA-p75NTR on cancer cells and their microenvironment, but also explains why
NGF … signaling within cancer cells that go beyond our classical knowledge on the NGF-TrkA-…

… signaling pathways downstream of the NGF-induced TrkA activation event. Many of these
downstream effectors are well characterized historic drug targets for oncology and a host of …

… NGF agonist, able to act specifically at the TrkA receptor, may be beneficial for the treatment
of … phase III clinical trail, recombinant human NGF was administered to 1019 patients with …

… This phase will also have the secondary objective of assessing the direct involvement of
NGF as a target of the therapy by measuring the NGF levels at pre- and posttreatment time …

… The generation of a small-molecule antagonist able to selectively disrupt the interaction
between NGF and TrkA is, therefore, an obvious therapeutic target and may help circumvent …

… TrkA is the high affinity catalytically active receptor for NGF. NGF binding to TrkA leads to
the phosphorylation of TrkA and activation of its downstream targets, such as protein kinase B (…

… Although K252a can inhibit several tyrosine kinase receptors, including Met and the epidermal
growth factor receptor, at the concentration used in our studies, its specificity for TrkA is …

… and the sensitivity of neurons to the trophic action of NGF. This evidence suggests … NGF/TrkA
signaling pathway is involved in AD pathogenesis and can be used as a therapeutic target. …

… and NGF in various subtypes of lung cancer is still unclear [101]… TrkA and NGF in squamous
cell carcinoma were upregulated, indicating that lung cancer drugs that target the NGF–TrkA …